Elanco Animal Health Incorporated (ELAN) Analyst/Investor Day Transcript

Elanco Animal Health Incorporated (ELAN) Analyst/Investor Day Transcript

Seeking Alpha • Dec 12, 2025

All You Need to Know About Elanco Animal Health (ELAN) Rating Upgrade to Buy

Elanco Animal Health (ELAN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Dec 12, 2025

Animal Health Focused Elanco Details Pipeline Momentum, US Investments, Cost-Saving Plans

On Tuesday, Elanco Animal Health Incorporated (NYSE: ELAN) used its first Investor Day in five years to signal a turning point for the company, outlining a more focused strategy aimed at sustainable growth, margin expansion, and a stronger balance sheet.

Benzinga • Dec 11, 2025

How Protein And Pets Drove Elanco Animal Health's 79% Gain In 2025

Elanco Animal Health CEO Jeff Simmons says the company is in the best position it's been in years. Elanco stock has surged in 2025.

Investors Business Daily • Dec 9, 2025

Elanco Investor Day Defines New Era as Sustainable Growth Company

Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to

PRNewsWire • Dec 9, 2025

Elanco Animal Health Incorporated (ELAN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Elanco Animal Health Incorporated (ELAN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 4, 2025

Elanco Animal Health Incorporated (ELAN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Elanco Animal Health Incorporated (ELAN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 3, 2025

Elanco executive appointed as Neurizon's Board Observer

MELBOURNE, Australia , Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.

PRNewsWire • Nov 26, 2025

Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats

The U.S. Food and Drug Administration on Friday authorized emergency use of Elanco Animal Health's chewable tablet to treat the infestation of a parasite in cats known as New World screwworm.

Reuters • Nov 21, 2025

Elanco Animal Health Stock Is Undervalued: Analyst

As the pet care industry experiences rapid growth, pharmaceutical companies are increasingly focusing on developing innovative treatments for companion animals.

Benzinga • Nov 21, 2025